Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30340758 | 1.00 | MAPT (0.43) | MAPTCYP3A4MAOATSHRTLR9 | |
| SCHEMBL10912768 | 0.94 | MAPT (0.45) | MAPTCYP3A4MAOATSHRTLR9 | |
| Hydrochloric Acid SCHEMBL7373928 | 0.93 | MAPT (0.44) | MAPTCYP3A4MAOATSHRTLR9 | |
| SCHEMBL21468538 | 0.88 | L3MBTL1 (0.39) | MAPTCYP3A4TSHRTLR9TLR8 | |
| SCHEMBL5564105 | 0.86 | MAOA (0.49) | MAPTCYP3A4MAOATSHRHTR2A | |
| SCHEMBL9331292 | 0.86 | HTR2C (0.54) | MAPTCYP3A4TLR9TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL9331810 | 0.85 | HTR2C (0.53) | MAPTCYP3A4MAOAHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL9331130 | 0.85 | HTR2C (0.53) | MAPTCYP3A4HTR2AHTR2CHTR2B | |
| SCHEMBL23090418 | 0.81 | KDM4E (0.46) | MAPTHCRTR1HCRTR2KDM4EALDH1A1 | |
| SCHEMBL18122551 | 0.81 | HTR2C (0.56) | MAPTTLR9TLR8TLR7HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995056-B2 | Direct C—H amination and aza-annulation | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-05-04 | — | — | US | disclosed |
| US-10995056-B2 | Direct C—H amination and aza-annulation | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-05-04 | — | — | US | disclosed |
| WO-2020108688-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE FOR NUCLEAR-MEDICAL IMAGING | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) | 2020-06-04 | — | — | WO | disclosed |
| US-20190152892-A1 | DIRECT C-H AMINATION AND AZA-ANNULATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190152892-A1 | DIRECT C-H AMINATION AND AZA-ANNULATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-05-23 | — | — | US | disclosed |
| WO-2018013540-A1 | DIRECT C-H AMINATION AND AZA-ANNULATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-18 | — | — | WO | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995056-B2 | Direct C—H amination and aza-annulation | AOC3, ALKBH3, AZI2 | MAPT 4598/4885CYP3A4 672/4885MAOA 136/4885 |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | MAPT 4777/4885CYP3A4 1715/4885MAOA 200/4885 |
| US-20190152892-A1 | DIRECT C-H AMINATION AND AZA-ANNULATION | AOC3, ALKBH3, AZI2 | MAPT 4580/4885CYP3A4 626/4885MAOA 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.